Patents by Inventor Vijay Sagar Madamsetty

Vijay Sagar Madamsetty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
    Patent number: 10611796
    Abstract: The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide, at least two co-lipids, a therapeutic agent, and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering a therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 7, 2020
    Assignees: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, MAYO CLINIC
    Inventors: Vijay Sagar Madamsetty, Arabinda Chaudhuri, Debabrata Mukhopadhyay
  • METHOD FOR REGRESSING PANCREATIC TUMOR BY A LIPOSOMAL FORMULATION ALONG WITH DNA VACCINES
    Publication number: 20170267719
    Abstract: The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK-lipopeptide, at least two co-lipids, therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).
    Type: Application
    Filed: March 16, 2017
    Publication date: September 21, 2017
    Inventors: Vijay Sagar Madamsetty, Arabinda Chaudhuri, Debabrata Mukhopadhyay